Login 
January 28, 2025
Ocubio Announces the Launch of the First Qualified Autologous Serum Eye Drops
Miami, FL – February 3rd, 2025 – Ocubio, a pioneering pharmaceutical company focused on innovative eye care solutions, is excited to announce the launch of its first product, Qualified Autologous Serum Eye Drops (qASED). This groundbreaking treatment is designed to provide superior support for patients with ocular surface disorders, utilizing the healing properties of autologous serum.
Developed from the latest research at the renowned Bascom Palmer Eye Institute, the #1 eye hospital in the United States, qASED harnesses the power of the patient’s own serum, which contains vital growth factors, nutrients, and anti-inflammatory agents essential for promoting eye health. This advanced formulation offers a safe and effective alternative for individuals suffering from conditions such as dry eye syndrome, ocular surface disease, and post-surgical recovery.
The launch of qASED marks a significant milestone for Ocubio, which aims to improve the quality of life for patients through innovative therapies. “We are thrilled to introduce qASED to the market,” said Dr. Alfonso L. Sabater, CEO of Ocubio. “Our mission is to revolutionize eye care by providing safe, effective and fully validated patient-centered solutions, and qASED is a testament to that commitment.”
Ocubio is set to initiate a soft launch of the product in February, with full commercial availability beginning in April. The company has already established partnerships that will facilitate access to this groundbreaking therapy for thousands of patients each year.
For more information about Ocubio and its Qualified Autologous Serum Eye Drops, please visit ocubio.com or contact info@ocubio.com
About Ocubio
Ocubio is a forward-thinking pharmaceutical company dedicated to developing innovative treatments for ocular surface diseases. With a strong foundation in research and a commitment to patient care, Ocubio aims to lead the way in advanced eye care solutions.
